Benefit of Prompt Vs Delayed Initiation of Triple Therapy Following an Exacerbation in Patients with COPD in Japan: A Retrospective Cohort Study

References

• Forum of International Respiratory Societies (FIRS). The global impact of respiratory disease; 2021. Available from: https://www.firsnet.org/images/publications/FIRS_Master_09202021.pdf. Accessed December 13, 2022.
   Google Scholar
• Takemura H, Hida W, Sasaki T, Sugawara T, Sen T. Prevalence of chronic obstructive pulmonary disease in Japanese people on medical check-up. Tohoku J Exp Med. 2005;207(1):41–50. doi:10.1620/tjem.207.41
   PubMed Web of Science ®Google Scholar
• Igarashi A, Fukuchi Y, Hirata K, et al. COPD uncovered: a cross-sectional study to assess the socioeconomic burden of COPD in Japan. Int J Chron Obstruct Pulmon Dis. 2018;13:2629–2641. doi:10.2147/COPD.S167476
   PubMed Web of Science ®Google Scholar
• Minakata Y, Ichinose M. [Epidemiology of COPD in Japan]. Nihon Rinsho. 2011;69(10):1721–1726. Japanese.
   PubMedGoogle Scholar
• Blasi F, Cesana G, Conti S, et al. The clinical and economic impact of exacerbations of chronic obstructive pulmonary disease: a cohort of hospitalized patients. PLoS One. 2014;9(6):e101228. doi:10.1371/journal.pone.0101228
   PubMed Web of Science ®Google Scholar
• Bogart M, Stanford RH, Reinsch T, Hull M, Buikema A, Hulbert E. Clinical characteristics and medication patterns in patients with COPD prior to initiation of triple therapy with ICS/LAMA/LABA: a retrospective study. Respir Med. 2018;142:73–80. doi:10.1016/j.rmed.2018.07.009
   PubMed Web of Science ®Google Scholar
• Dalal AA, Shah M, D’Souza AO, Rane P. Costs of COPD exacerbations in the emergency department and inpatient setting. Respir Med. 2011;105(3):454–460. doi:10.1016/j.rmed.2010.09.003
   PubMed Web of Science ®Google Scholar
• Mannino D, Bogart M, Germain G, et al. Benefit of prompt versus delayed use of single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) following a COPD exacerbation. Int J Chron Obstruct Pulmon Dis. 2022;17:491–504. doi:10.2147/COPD.S337668
   PubMed Web of Science ®Google Scholar
• Sicras Mainar A, Huerta A, Navarro Artieda R, Monso E, Landis SH, Ismaila AS. Economic impact of delaying initiation with multiple-inhaler maintenance triple therapy in Spanish patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2019;14:2121–2129. doi:10.2147/COPD.S211854
   PubMed Web of Science ®Google Scholar
• Decramer M, Cooper CB. Treatment of COPD: the sooner the better? Thorax. 2010;65(9):837–841. doi:10.1136/thx.2009.133355
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for Diagnosis, Management and Prevention 2023 Update; 2023. Available from: https://goldcopd.org/wp-content/uploads/2023/03/GOLD-2023-ver-1.3-17Feb2023_WMV.pdf. Accessed November 17, 2022.
   Google Scholar
• Japanese Respiratory Society. Guidelines for COPD (chronic obstructive pulmonary disease) diagnosis and treatment [6th edition]; 2022.
   Google Scholar
• Gaduzo S, McGovern V, Roberts J, Scullion JE, Singh D. When to use single-inhaler triple therapy in COPD: a practical approach for primary care health care professionals. Int J Chron Obstruct Pulmon Dis. 2019;14:391–401. doi:10.2147/COPD.S173901
   PubMed Web of Science ®Google Scholar
• Halpin DMG, Worsley S, Ismaila AS, et al. INTREPID: single- versus multiple-inhaler triple therapy for COPD in usual clinical practice. ERJ Open Res. 2021;7(2):00950–02020. doi:10.1183/23120541.00950-2020
   PubMedGoogle Scholar
• Pharmaceuticals and Medical Devices Agency (PMDA). List of approved products - new drugs approved in FY 2013; 2013. Available from: https://www.pmda.go.jp/files/000232771.pdf. Accessed November 17, 2022.
   Google Scholar
• Pharmaceuticals and Medical Devices Agency (PMDA). List of approved products - new drugs approved in FY 2008; 2008. Available from: https://www.pmda.go.jp/files/000232775.pdf. Accessed November 17, 2022.
   Google Scholar
• Pharmaceuticals and Medical Devices Agency (PMDA). List of approved products - new drugs approved in FY 2004; 2004. Available from: https://www.pmda.go.jp/files/000232776.pdf. Accessed November 17, 2022.
   Google Scholar
• GlaxoSmithKline KK Serevent Diskus® [package insert]; 2022. (in Japanese). Available from: https://www.info.pmda.go.jp/go/pack/2259708G1022_1_18/?view=frame&style=XML&lang=ja. Accessed February 24, 2023.
   Google Scholar
• Pharmaceuticals and Medical Devices Agency (PMDA). List of approved products - new drugs approved in FY 2018; 2018. Available from: https://www.pmda.go.jp/files/000235288.pdf. Accessed November 17, 2022.
   Google Scholar
• Pharmaceuticals and Medical Devices Agency (PMDA). List of approved products - new drugs approved in FY 2019; 2019. Available from: https://www.pmda.go.jp/files/000235289.pdf. Accessed November 17, 2022.
   Google Scholar
• Sansbury LB, Wood RP, Anley GA, Nam Y, Ismaila AS. Quantifying the economic impact of delayed multiple-inhaler triple therapy initiation in patients with COPD: a retrospective cohort study of linked electronic medical record and hospital administrative data in England. Int J Chron Obstruct Pulmon Dis. 2021;16:2795–2808. doi:10.2147/COPD.S312853
   PubMed Web of Science ®Google Scholar
• Ismaila A, Jakubanis R, Holbrook T, Punekar Y, Wood R, Meeraus W. Cost impact of time to initiation of triple therapy in COPD patients in Japan: a retrospective analysis of healthcare claims data. Eur Resp J. 2017;50(suppl 61):PA2788. doi:10.1183/1393003.congress-2017.PA2788.
   Google Scholar
• Medical Data Vision (MDV). About MDV database. Available from: https://en.mdv.co.jp/about-mdv-database/. Accessed November 17, 2022.
   Google Scholar
• Laurent T, Simeone J, Kuwatsuru R, et al. Context and considerations for use of two Japanese real-world databases in Japan: Medical Data Vision and Japanese Medical Data Center. Drugs Real World Outcomes. 2022;9(2):175–187. doi:10.1007/s40801-022-00296-5
   PubMedGoogle Scholar
• Statistics of Japan. e-Stat Consumer Price Index Monthly Reports; 2021. Available from: https://www.e-stat.go.jp/en/stat-search/files?page=1&layout=datalist&toukei=00200573&tstat=000001084976&cycle=1&tclass1=000001085955&tclass2val=0. Accessed February 24, 2023.
   Google Scholar
• Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130–1139. doi:10.1097/01.mlr.0000182534.19832.83
   PubMed Web of Science ®Google Scholar
• Flattet Y, Garin N, Serratrice J, Perrier A, Stirnemann J, Carballo S. Determining prognosis in acute exacerbation of COPD. Int J Chron Obstruct Pulmon Dis. 2017;12:467–475. doi:10.2147/COPD.S122382
   PubMed Web of Science ®Google Scholar
• Tsutsue S, Tobinai K, Yi J, Crawford B. Nationwide claims database analysis of treatment patterns, costs and survival of Japanese patients with diffuse large B-cell lymphoma. PLoS One. 2020;15(8):e0237509. doi:10.1371/journal.pone.0237509
   PubMed Web of Science ®Google Scholar